Cross-Sectional Study to Determine the Prevalence of Hepatitis B and C Virus Infection in High Risk Groups in the Northeast Region of Brazil

Jakeline Ribeiro Barbosa 1,2, Cristianne Sousa Bezerra 1,2, Filipe Aníbal Carvalho-Costa 3, Carolina Pimentel de Azevedo 1, Geane Lopes Flores 1, Jeová Keny Baima Colares 2,4, Danielle Malta Lima 2,4, Elisabeth Lampe 1 and Lívia Melo Villar 1,*

1 Viral Hepatitis Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro 21040-900, Brazil; jakelinebarbosa@gmail.com (J.R.B.); tiannebezerra@gmail.com (C.B.); carolazevedo09@msn.com (C.P.d.A.); geane@ioc.fiocruz.br (G.L.F.); elampe@ioc.fiocruz.br (E.L.)
2 Postgraduate Programme in Pathology, Federal University of Ceará State, Fortaleza CE 60430-160, Brazil; kenycolares@unifor.br (J.K.B.C.); danimalta37@gmail.com (D.M.L.)
3 Laboratory of Epidemiology and Molecular Systematics, Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro 21040-900, Brazil; guaratiba@ioc.fiocruz.br
4 Postgraduate Programme in Medical Sciences, University of Fortaleza, Fortaleza CE 60811-905, Brazil
* Correspondence: lvillar@ioc.fiocruz.br or liviafiocruz@gmail.com; Tel.: +55-21-2562-1918

Academic Editor: Paul B. Tchounwou
Received: 11 May 2017; Accepted: 30 June 2017; Published: 17 July 2017

Abstract: Background: HBV (Hepatitis B Virus) and HCV (Hepatitis C Virus) infections are more prevalent in vulnerable populations than the general population. The objective of this study was to investigate the prevalence of HBV and HCV infection in HIV-positive patients (GI), chronic renal failure (CRF) patients (GII) and coagulation disorder individuals (GIII).

Methods: A cross-sectional study was conducted from June 2014 to March 2015. Serum samples were tested for markers of hepatitis B and C by enzyme-linked immunosorbent assay (ELISA). Sociodemographic, epidemiological, clinical and laboratory data and accompanying statistical analyses were performed using Epi Info™ 7.

Results: A total of 348 individuals were recruited, i.e., 154 HIV-positive, 143 CRF and 51 coagulopathy patients. Among them, more than 66% were men, and the predominant age group was 26–35 years in GI and 56–65 years in GIII. Most patients had more than 8 years of education (66.2% in GI, 60.6% in GII and 46.1% in GIII), with a family income between 100–400 dollars in more than 48% of patients. The prevalence of the HBsAg marker was 3.9%, 7% and 3.9%, total anti-HBc was 28.6%, 55.9% and 31.4%, and anti-HCV was 1.3%, 12.6% and 47% for GI, GII and GIII, respectively. However, the prevalence of anti-HBs was greater than 70% in all groups.

Conclusions: This study shows a high prevalence of HBV and HCV among specific groups compared to the general population. Factors such as age, income, number of sexual partners, sexually transmitted disease burden, blood transfusion history or blood products and blood transfusions before 1994 were associated with a higher prevalence for these infections.

Keywords: prevalence; hepatitis B virus; hepatitis C virus; human immunodeficiency virus 1; haemodialysis; coagulopathy

1. Introduction

Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) can cause acute and chronic liver disease, which can progress to cirrhosis, liver failure and/or hepatocellular carcinoma [1,2]. An estimated 240 million people are chronically infected with hepatitis B virus, which is defined as testing positive...
for hepatitis B surface antigen for at least 6 months. Of these cases, more than 686,000 people die every year due to hepatitis B complications, such as cirrhosis and liver cancer [3]. In Brazil, the prevalence of antibodies against Hbc (anti-Hbc) ranged from 8.1% to 10.3% in the Federal District and the Central-West region, while the prevalence of HBsAg antigen was 0.19% in the Northeast, 0.47% in the Central-West and 0.60% in the Federal District [4].

It is estimated that approximately 130–150 million people worldwide have chronic hepatitis C infection and that approximately 700,000 people die each year from liver disease related to hepatitis C [3]. In Brazil, the prevalence of Hepatitis C antibodies (anti-HCV) was 1.38% in the state capitals of the five macro-regions and the Federal District, and it varied from 0.68% in the Northeast to 2.10% in the North region of the country [5].

HBV and HCV infections are prevalent worldwide, especially in the most vulnerable populations, such as patients infected with human immunodeficiency virus (HIV), patients with chronic renal failure (CRF) that are on haemodialysis and patients with coagulation disorders compared to the general population [6–14].

HBV and HCV prevalence is high among individuals infected with HIV due to the shared routes of transmission of infection, such as injecting drug use, blood transfusion and sexual intercourse [11,13,15]. In Brazil, the prevalence of HIV/HBV co-infection ranged from 2.8% to 10.3%, while HIV/HCV co-infection ranged from 4.6% to 6.4% [14,16,17]. The high prevalence of co-infected individuals varied according to the specific region of the country [18].

CRF patients are considered high-risk for acquiring HBV and HCV infections because parenteral exposure during the dialysis treatment is a major route of transmission. These infections negatively impact the survival of the haemodialysis patients and those undergoing renal transplant. In Brazil, the prevalence of anti-HBc and HBsAg were 34.1% and 15.4%, respectively, while the prevalence of anti-HCV ranged from 12% to 33.9% in CRF patients [7–9,19].

Hereditary coagulopathies are the result of deficiency diseases of one or more plasma clotting proteins. Among the inherited bleeding disorders, haemophilia and Von Willebrand’s Disease (VWD) are the most common. Haemophilia A and B are X-linked recessive bleeding disorders included among rare diseases and caused by mutations in the factor VIII and factor IX genes. Both factors take part in the intrinsic pathway of blood coagulation, and affected individuals have severe, moderate and mild forms of the diseases, which are defined by factor plasma levels [20–22]. However, VWD is caused by a decrease in or dysfunction of the protein called Von Willebrand Factor (VWF) and affects both genders. The diversity of mutations results in various clinical manifestations, e.g., platelet dysfunction associated with decreased serum factor VIII levels [21].

Treatment of coagulopathies involves the replacement of deficient clotting factors, which is administered as processed concentrates from blood donors and/or synthesized by the pharmaceutical industry. Clotting factor replacement increases the survival of coagulopathy patients. However, these patients are at an increased risk of infection with HBV and HCV because of multiple blood transfusions and frequent parenteral exposure. In Brazil, the prevalence of HBV infection ranged from 0.7% to 2.3%, while HCV infection ranged from 2.5% to 34.9% in this population [12,22,23].

Brazilian studies to determine the prevalence of HBV and HCV infection are common in the general population, mainly in the Southeast region of the country. However, few studies have been conducted including these specific populations in Northeast Brazil, such as HIV-positive individuals, patients with CRF on haemodialysis and patients with coagulation disorders [17]. Identifying the prevalence of these infections in these more vulnerable groups is critical to diagnose, treat and prevent the spread of these infections. Therefore, this study aimed to investigate the prevalence of HBV and HCV infection in HIV-positive patients, CRF patients on haemodialysis and coagulation disorders in Fortaleza-CE, Brazil.
2. Materials and Methods

2.1. Study Design, Sampling and Population

A cross-sectional study was conducted during the period of June 2014 to March 2015. Sociodemographic data from subjects were obtained through a questionnaire, including the variables of income, risk behaviour, age, gender, marital status and education.

Three groups included were as follows: I—HIV-infected patients \( n = 154 \); II—patients with CRF on haemodialysis \( n = 143 \); and III—patients with coagulopathy (haemophilia or von Willebrand disease) \( n = 51 \). These groups were recruited, respectively, from a private HIV/AIDS clinic, private haemodialysis clinic and public Hematology and Hemotherapy Center of Ceará city, all of which are located in Fortaleza, Northeast region of Brazil.

The inclusion criteria for the selection of participants were as follows: individuals of both genders, aged 18 years or more and referral to one of the three health service centres involved in this study (group I, II or III). In addition, diagnostic criteria for HIV (group I) was considered, which included individuals who tested positive using the HIV 1/2 STAT-PAK® kit (Chembio Diagnostic Systems Inc., Medford, NY, USA) and who may or may not have undergone antiretroviral treatment for HIV. Group II included CRF patients who were already diagnosed and undergoing haemodialysis treatment in the nephrology clinic. Group III included patients with haemophilia- (A and B) and VWD-type coagulopathies who were diagnosed by clinical and laboratory parameters at the Center of Hematology of Ceará, where patients are monitored since childhood.

2.2. Laboratory Analysis

Blood samples (10 mL) were collected from each subject by venipuncture, centrifuged to obtain serum and stored at \(-20^\circ C\) until analysis. Serum samples were tested for markers of hepatitis B and C by enzyme-linked immunosorbent assay (ELISA) using commercially available kits. All samples were examined for the presence of HBsAg (Bioelisa® HBsAg, Biokit, Llíçà d’Amunt, Spain), total anti-HBc (anti-HBc Bioelisa®, Biokit), anti-HBs (anti-HBs Bioelisa®, Biokit) and anti-HCV (Murex anti-HCV version 4.0®, DiaSorin, Saluggia, Italy) according to the manufacturer’s instructions. Reactive and indeterminate samples were retested in duplicate and indeterminate results were excluded. Serological tests were performed at the Viral Hepatitis Laboratory of the Oswaldo Cruz Institute—FIOCRUZ.

2.3. Data Analysis

Sociodemographic, epidemiological, clinical and laboratory data were entered Microsoft Access® database (Microsoft, Redmond, WA, USA). Statistical analyses were performed using Epi Info™ 7 (Epi Info Software, CDC, Atlanta, GA, USA). Prevalence rates in distinct groups were compared with Fisher’s exact test. Results with \( p \) values (two-tailed) < 0.05 were considered statistically significant.

2.4. Ethical Aspects

The Ethics Committee of FIOCRUZ approved this study under the numbers 34049514.7.3006.5258 and 34049514.7.3009.5051. All patients included in the study provided informed consent and study protocols were followed according to the ethical guidelines of the 1975 Declaration of Helsinki.

3. Results

A total of 348 patients were recruited for this study, which included 154 HIV-infected patients, 143 patients with CRF on haemodialysis and 51 patients with coagulopathies, with at least 68% of these patients being men. More than 55% were 26–35 years of age in the HIV group (GI) and coagulopathy group (GIII), while the predominant age was 56–65 years in haemodialysis group (GII) (Table 1).

Regarding marital status, 70.8% of group I and 66.7% of group III were single. However, approximately 50% of group II subjects were married or had a stable union. The education of the
participants was greater than 8 years in 66.2% of group I, 60.6% of group III and 46.1% of group II. Of which, more than 48% of participants had a monthly family per capita income between 100 and 400 dollars.

As shown in Table 2, the prevalence of the HBV surface antigen (HBsAg) was 3.9%, 7% and 3.9% for groups I, II and III, respectively. While the prevalence of total anti-HBc marker was 28.6%, 55.9% and 31.4% in GI, GII and GIII, respectively, anti-HBs prevalence was greater than 70% in all groups. The presence of total anti-HBc and anti-HBs, which indicated immunity after HBV infection, was 21.4% (33/154) in group I, 38.5% (55/143) in group II and 29.4% (15/51) in group III.

**Table 1. Sociodemographic characteristics of the sample.**

| Variable                  | HIV Positive (n = 154) | CRF α Haemodialysis (n = 143) | Coagulopathy (n = 51) |
|---------------------------|-----------------------|-------------------------------|-----------------------|
| Gender                    | N (%)                 | N (%)                         | N (%)                 |
| Male                      | 131 (85.0)            | 98 (68.5)                     | 50 (98.0)             |
| Female                    | 23 (15.0)             | 45 (31.5)                     | 1 (2.0)               |
| Age group (years)         |                       |                               |                       |
| 18–25                     | 23 (14.9)             | 1 (0.7)                       | 15 (29.4)             |
| 26–35                     | 58 (37.7)             | 24 (16.8)                     | 19 (37.3)             |
| 36–45                     | 46 (29.9)             | 27 (18.9)                     | 12 (23.5)             |
| 46–55                     | 19 (12.3)             | 34 (23.8)                     | 4 (7.8)               |
| 56–65                     | 7 (4.5)               | 36 (25.2)                     | 0 (0.0)               |
| ≥66                       | 1 (0.6)               | 21 (14.7)                     | 0 (0.0)               |
| Unknown                   | 0 (0.0)               | 0 (0.0)                       | 1 (2.0)               |
| Marital status            |                       |                               |                       |
| Married/stable union      | 44 (28.6)             | 72 (50.3)                     | 17 (33.3)             |
| Single                    | 109 (70.8)            | 71 (49.7)                     | 34 (66.7)             |
| Unknown                   | 1 (0.6)               | 0 (0.0)                       | 0 (0.0)               |
| Education                 |                       |                               |                       |
| Illiterate                | 2 (1.3)               | 11 (7.7)                      | 2 (3.9)               |
| 1 to 8 years              | 50 (32.5)             | 66 (46.1)                     | 18 (35.3)             |
| >8 years                  | 102 (66.2)            | 66 (46.1)                     | 31 (60.8)             |
| Monthly family per capita income |                   |                               |                       |
| zero                      | 8 (5.2)               | 4 (2.8)                       | 4 (7.8)               |
| <100 dollars              | 16 (10.4)             | 22 (15.4)                     | 13 (25.5)             |
| 100 to 400 dollars        | 75 (48.7)             | 82 (57.3)                     | 25 (49.0)             |
| >400 dollars              | 55 (35.7)             | 35 (24.5)                     | 9 (17.6)              |

* CRF = chronic renal failure.

**Table 2. HBV and HCV markers in population studied.**

| Variable                  | HIV-Positive (n = 154) | CRF α Haemodialysis (n = 143) | Coagulopathy (n = 51) |
|---------------------------|-----------------------|-------------------------------|-----------------------|
| Marker of Exposure to HBV |                       |                               |                       |
| HBsAg reactive            | 6 (3.9%)              | 10 (7.0%)                     | 2 (3.9%)              |
| Total anti-HBc reactive   | 44 (28.6%)            | 80 (55.9%)                    | 16 (31.4%)            |
| Anti-HBs reactive         | 115 (74.7%)           | 103 (72.0%)                   | 37 (72.5%)            |
| Anti-HBc reactive/Anti-HBs reactive | 33 (21.4%) | 55 (38.5%) | 15 (29.4%) |

**Marker of Exposure to HCV**

| Variable          | HIV-Positive (n = 154) | CRF α Haemodialysis (n = 143) | Coagulopathy (n = 51) |
|-------------------|------------------------|-------------------------------|-----------------------|
| Anti-HCV reactive | 2 (1.3%)               | 18 (12.6%)                    | 24 (47.0%)            |

* CRF = chronic renal failure.

The prevalence of HCV antibody (anti-HCV) was 1.3% (2/154), 12.6% (18/143) and 47% (24/51) in HIV-positive, CRF-haemodialysis and coagulopathy groups, respectively.
Table 3 shows the prevalence of total anti-HBc antibody in relation to the risk factors for each group, with males being the most prevalent, i.e., 31.1% (41/131) of group I, 56.1% (55/98) of group II, 32% (16/50) of group III. The prevalence of total anti-HBc in the respective groups was 36.9% (17/46) in the age range of 36–45 years, 69.4% (25/36) in the age range of 56–65 years, and 50% (6/12) in the range of 36–45 years. There was a statistically significant difference between the frequency of this marker in the different age groups of group II ($p = 0.013$) and group III ($p = 0.025$).

Regarding the monthly family per capita income, the highest prevalence of anti-HBc was among individuals without income in group I (50%, 4/8), among individuals with an income higher than $400 in group II (69.4%, 25/36) and among those without income in group III (75%, 3/4, $p = 0.059$).

Regarding sexual behaviour, men who had sex with men (MSM) had a higher prevalence of total anti-HBc (34.5%, 30/87) in group I, while the highest prevalence of anti-HBc in groups II and III (55.9%, 52/93; 32.6%, 16/49) was among non-MSM subjects. Regarding the number of sexual partners in the previous year, the prevalence of anti-HBc in group I was higher among those who had more than 10 partners ($p = 0.003$). In group II, anti-HBc was more prevalent among those who had six partners or more. While in group III, it was higher among those who had only one partner in the last twelve months (45%, 9/20). There was no statistically significant correlation between the use of a condom and the frequency of anti-HBc in the groups.

The prevalence of anti-HBc was higher for those individuals with coagulopathy (GIII) who had already undergone blood or plasma transfusion ($p = 0.018$) and for blood transfusions performed before 1994 ($p = 0.076$), since testing for anti-HCV became a mandatory component of serological screening conducted at Brazilian blood banks after November 1993.

Table 3. Prevalence of anti-HBc antibody in population groups with a high risk for HBV infection.

| Variable                        | HIV Reactive | CRF (n = 143) | Coagulopathy (n = 51) |
|---------------------------------|--------------|---------------|-----------------------|
|                                 | Positive/Tested | Positive/Tested | Positive/Tested |
|                                 | (% Positive)   | (% Positive)   | (% Positive)         | p-Value | p-Value | p-Value |
| Gender *                        | Male          | 41/131 (31.3)  | 55/98 (56.1)          | 0.084   | 16/50 (32.0) | 1 |
|                                 | Female        | 3/23 (13.0)    | 25/45 (55.5)          | 1       | 0/1 (0.0)    | 1 |
| Age Group (years) **            | 18–25         | 5/22 (22.7)    | 0/1 (0.0)             | 0.678   | 1/15 (6.7)   | 0.025 |
|                                 | 26–35         | 15/58 (25.9)   | 11/24 (45.8)          | 0.013   | 7/19 (36.8)  | 0.007 |
|                                 | 36–45         | 17/46 (36.9)   | 14/27 (51.8)          | 0.013   | 6/12 (50.0)  | 0.007 |
|                                 | 46–55         | 5/19 (26.3)    | 18/34 (52.9)          | 0.013   | 2/4 (50.0)   | 0.007 |
|                                 | 56–65         | 2/7 (28.6)     | 25/36 (69.4)          | 0.013   | 0/0 (0.0)    | 0.007 |
|                                 | ≥66           | 0/1 (0.0)      | 12/21 (57.1)          | 0.013   | 0/0 (0.0)    | 0.007 |
| Marital Status *                | Married/stable union | 12/44 (27.3) | 39/72 (54.2)          | 0.737   | 6/17 (35.3)  | 0.753 |
|                                 | Single        | 32/110 (29.1)  | 41/71 (57.8)          | 0.737   | 10/34 (29.4) | 0.753 |
| Education **                    | Illiterate    | 0/2 (0.0)      | 6/11 (54.5)           | 0.091   | 1/2 (50.0)   | 0.570 |
|                                 | 1 to 8 years  | 11/35 (31.4)   | 28/56 (50.0)          | 0.406   | 1/11 (9.1)   | 0.113 |
|                                 | >8 years      | 33/117 (28.2)  | 46/76 (60.5)          | 0.406   | 13/37 (35.1) | 0.11 |
| Monthly Family per Capita Income ** | 0 <100 dollars | 4/8 (50.0)    | 0/1 (0.0)             | 0.837   | 3/4 (75.0)   | 0.121 |
|                                 | 100 to 400 dollars | 18/75 (24.0) | 43/82 (52.4)          | 0.059   | 6/25 (24.0)  | 0.121 |
|                                 | >400 dollars  | 19/55 (34.5)   | 25/36 (69.4)          | 0.059   | 3/10 (30.0)  | 0.121 |
| Sexual Orientation (Males) *    | MSM           | 30/97 (34.5)   | 2/4 (50.0)            | 0.312   | 16/49 (32.6) | 0.202 |
|                                 | Non-MSM       | 10/40 (25.0)   | 52/93 (55.9)          | 0.312   | 16/49 (32.6) | 0.202 |
| Variable                      | HIV Reactive (n = 154) | p-Value | CRF (n = 143) | p-Value | Coagulopathy (n = 51) | p-Value |
|-------------------------------|------------------------|---------|---------------|---------|-----------------------|---------|
|     | Positive/Tested (%) Positive |         | Positive/Tested (%) Positive |         | Positive/Tested (%) Positive |         |
|     | (%) Positive |               | (%) Positive |               | (%) Positive |               |
|     |            |               |               |               |               |         |
| Sexual Partner—Last Year **   |                        |         |               |         |                        |         |
| 1   | 11/66 (16.7) | 0.003   | 40/72 (55.5) | 0.267   | 9/20 (45.0) | 0.543   |
| <5  | 20/49 (40.8) |         | 11/22 (50.0) |         | 3/16 (18.7) |         |
| 6 to 10 | 7/15 (46.7) |         | 2/2 (100.0) |         | 0/4 (0.0) |         |
| >10 | 3/6 (50.0) |         | 3/3 (100.0) |         | 1/3 (33.3) |         |
| Unknown  | 3/18 (16.7) |         | 24/44 (54.5) |         | 3/8 (37.5) |         |
| Condom Use **                 |                        |         |               |         |                        |         |
| Always | 29/112 (25.9) | 0.422   | 21/35 (60.0) | 0.285   | 6/17 (35.3) | 0.704   |
| Sometimes | 12/29 (41.4) |         | 14/21 (66.7) |         | 6/20 (30.0) |         |
| Never | 2/8 (25.0) |         | 42/81 (51.8) |         | 3/9 (33.3) |         |
| Unknown  | 1/5 (20.0) |         | 3/6 (50.0) |         | 1/5 (20.0) |         |
| ARV Treatment                 |                        |         |               |         |                        |         |
| Yes | 6/123 (4.9) | 0.600   |               |         |                        |         |
| No | 0/31 (0.0) |         |               |         |                        |         |
| Unknown  | 12/194 (6.2) |         |               |         |                        |         |
| Sexually Transmitted Infection |                        |         |               |         |                        |         |
| Yes | 29/69 (42.0) | 0.001   | 23/39 (58.9) | 0.707   | 8/10 (80.0) | 0.000   |
| No | 15/84 (17.8) |         | 56/102 (54.9) |         | 8/40 (20.0) |         |
| Unknown  |               |         |               |         |                        |         |
| Oral Intercourse              |                        |         |               |         |                        |         |
| Yes | 37/115 (32.2) | 0.092   | 31/54 (57.4) | 1     | 7/25 (28.0) | 0.537   |
| No | 6/37 (16.2) |         | 34/60 (56.7) |         | 8/21 (38.1) |         |
| Unknown  | 1/2 (50.0) |         | 15/29 (51.7) |         | 1/5 (20.0) |         |
| Anal Intercourse              |                        |         |               |         |                        |         |
| Yes | 35/114 (30.7) | 0.302   | 26/50 (52.0) | 0.459   | 6/19 (31.6) | 1     |
| No | 8/38 (21.0) |         | 43/72 (59.7) |         | 9/27 (33.3) |         |
| Unknown  | 1/2 (50.0) |         | 11/21 (52.4) |         | 1/5 (20.0) |         |
| Tattoo                         |                        |         |               |         |                        |         |
| Yes | 12/42 (28.6) |               | 5/13 (38.5) | 0.243   | 2/6 (33.3) | 1     |
| No | 32/112 (28.6) |               | 75/130 (57.7) |         | 14/44 (31.8) |         |
| Unknown  | 0 |               | 0 |         | 0/1 (0.0) |         |
| Piercing                       |                        |         |               |         |                        |         |
| Yes | 4/15 (26.7) |               | 1/2 (50.0) | 1     | 1/2 (50.0) | 1     |
| No | 40/139 (28.8) |               | 79/141 (56.0) |         | 15/47 (31.9) |         |
| Unknown  | 0 |               | 0 |         | 0/2 (0.0) |         |
| Transfusion of Blood/Plasma    |                        |         |               |         |                        |         |
| Yes | 5/16 (31.2) | 0.779   | 51/90 (56.7) | 0.861   | 15/35 (42.8) | 0.018   |
| No | 39/136 (28.7) |         | 28/51 (54.9) |         | 1/15 (6.7) |         |
| Unknown  | 0/2 (0.0) |         | 1/2 (50.0) |         | 0/1 (0.0) |         |
| Transfusion before 1994        |                        |         |               |         |                        |         |
| Yes | 3/9 (37.5) | 0.569   | 11/15 (73.3) | 0.161   | 13/25 (52.0) | 0.076   |
| No | 1/8 (12.5) |         | 39/75 (52.0) |         | 2/11 (18.2) |         |
| Unknown  | 40/138 (29.0) |         | 30/53 (56.6) |         | 1/15 (6.7) |         |
| Attend Manicure                |                        |         |               |         |                        |         |
| Yes | 24/94 (25.5) | 0.460   | 45/80 (56.2) | 1     | 6/20 (30.0) | 1     |
| No | 19/59 (32.2) |         | 34/62 (54.8) |         | 10/30 (33.3) |         |
| Unknown  | 1/1 (100.0) |         | 1/1 (100.0) |         | 0/1 (0.0) |         |
| Injecting/Inhaled Drug Use     |                        |         |               |         |                        |         |
| Yes | 6/34 (23.5) | 0.525   | 3/8 (37.5) | 0.466   | 1/6 (16.7) | 0.649   |
| No | 36/120 (30.0) |         | 76/134 (56.7) |         | 15/43 (34.9) |         |
| Unknown  | 0 |         | 1/1 (100.0) |         | 0/2 (0.0) |         |

CRF = chronic renal failure; * Fisher’s exact test; ** chi-square test for trend.
Table 4 shows the prevalence of anti-HCV according to the socioeconomic and behavioural characteristics of each group; there was a prevalence of 4.3% (1/23) among females and 3.2% (1/131) among males in group II (15.3%, 15/98) and group III (48%, 24/50). The highest age range for anti-HCV was 46–55 years (5.2%, 1/19), 56–65 years (22.2%, 8/36) and 36–45 years (91.6%, 11/12) in GI, GII, and GIII, respectively. Married/stable union individuals and those with 1–8 years of education had a higher prevalence of anti-HCV.

Participants in this study with a monthly family per capita income of less than 100 dollars had a higher prevalence of anti-HCV in group I (6.4%, 1/16) and group II (14.3%, 3/21), while group III had a prevalence of 56% (14/25) among those with incomes of 100 to 400 dollars.

Regarding sexual behaviour, the prevalence of anti-HCV in group II was higher for those who had more numerous sexual partners in the last year, whereas in the case of groups I and III, the prevalence was higher for those with one sexual partner. The absence of a condom during intercourse and the practise of oral/anal intercourse were not statistically significant for anti-HCV positivity in these groups. Although inconsistent condom use presented a significant value of $p = 0.062$ in group II.

On the other hand, individuals with a sexually transmitted infection had a higher prevalence of anti-HCV in group I (2.9%, 2/69) and group III (80%, 8/10), with a significant $p$ value for the coagulopathy group ($p = 0.031$).

Regarding individuals who previously received a blood or plasma transfusion, the highest prevalence of anti-HCV was 15.5% (14/90) in group II and 60% (21/35) in group III, in which results for the coagulopathy group were statistically significant ($p = 0.004$). Moreover, individuals who received blood transfusions prior to 1994 were more inclined to HCV exposure and had an anti-HCV prevalence of 41.2% (7/17) and 64% (16/25), with $p = 0.004$ for the haemodialysis group (Table 4). On the other hand, the use of injectable drugs had a significant $p$ value ($p = 0.064$) in group II, albeit not statistically significant.

Table 4. Prevalence of anti-HCV antibody in population groups with a high risk for HCV infection.

| Variable                        | HIV Reactive ($n = 154$) | $p$-Value | CRF ($n = 143$) | $p$-Value | Coagulopathy ($n = 51$) | $p$-Value |
|---------------------------------|--------------------------|-----------|-----------------|-----------|-------------------------|-----------|
| Gender *                        |                          |           |                 |           |                         |           |
| Male                            | 1/131 (3.2)              | 0.277     | 15/98 (15.3)    | 0.182     | 24/50 (48.0)            | 1         |
| Female                          | 1/23 (4.3)               |           | 3/45 (6.7)      |           | 0/1 (0.0)               |           |
| Age Group (Years) **            |                          |           |                 |           |                         |           |
| 18–25                           | 0/22 (0.0)               |           | 0/1 (0.0)       |           | 2/15 (13.3)             |           |
| 26–35                           | 0/58 (0.0)               |           | 1/24 (4.1)      |           | 9/19 (47.4)             |           |
| 36–45                           | 1/46 (2.1)               | 0.367     | 5/27 (18.5)     | 0.394     | 11/12 (91.6)            | 0.474     |
| 46–55                           | 1/19 (5.2)               |           | 2/34 (5.9)      |           | 1/4 (25.0)              |           |
| 56–65                           | 0/7 (0.0)                |           | 8/36 (22.2)     |           | 0/0 (0.0)               |           |
| ≥66                             | 0/1 (0.0)                |           | 2/21 (9.5)      |           | 0/0 (0.0)               |           |
| Marital Status *                |                          |           |                 |           |                         |           |
| Married/stable union            | 1/44 (2.3)               | 0.491     | 9/72 (12.5)     | 1         | 11/17 (64.7)            | 0.135     |
| Single                          | 1/110 (0.9)              |           | 9/71 (12.7)     |           | 13/34 (38.2)            |           |
| Education *                     |                          |           |                 |           |                         |           |
| Illiterate                      | 0/2 (0.0)                |           | 1/11 (9.0)      |           | 1/2 (50.0)              |           |
| 1 to 8 years                    | 1/35 (2.8)               | 0.128     | 11/56 (19.6)    | 0.144     | 6/11 (54.5)             | 0.404     |
| >8 years                        | 1/117 (0.8)              |           | 6/76 (7.9)      |           | 16/37 (43.2)            |           |
| Monthly Family Per Capita Income ** |           |           |                 |           |                         |           |
| Zero                            | 0/8 (0.0)                | 0.481     | 0/1 (0.0)       | 0.412     | 4/4 (100.0)             | 0.210     |
| <100 dollars                    | 1/16 (6.4)               |           | 3/21 (14.3)     |           | 3/12 (25.0)             |           |
| 100 to 400 dollars              | 0/75 (0.0)               |           | 11/82 (13.4)    |           | 14/25 (56.0)            |           |
| >400 dollars                    | 1/55 (1.8)               |           | 3/36 (8.3)      |           | 3/10 (30.0)             |           |
### Table 4. Cont.

| Variable                              | HIV Reactive (n = 154) | p-Value | CRF (n = 143) | p-Value | Coagulopathy (n = 51) | p-Value |
|---------------------------------------|------------------------|---------|---------------|---------|-----------------------|---------|
|                                       | Positive/Tested (%)    |         | Positive/Tested (%) |         | Positive/Tested (%)    |         |
| **Sexual Orientation (Males) *       |                        |         |               |         |                       |         |
| MSM                                  | 1/87 (1.1)             | 1       | 1/4 (25.0)    | 0.495   | 0/0 (0.0)             | 1       |
| Non-MSM                              | 0/40 (0.0)             |         | 14/93 (15.0)  | 23/49 (46.9) |
| **Sexual Partner—Last Year α         |                        |         |               |         |                       |         |
| <5                                    | 1/66 (1.5)             | 0.331   | 6/72 (8.3)    | 0.214   | 13/21 (61.9)          | 0.214   |
| 6 to 10                               | 0/15 (0.0)             |         | 2/2 (100.0)   | 1/4 (25.0)  |
| >10                                   | 0/6 (0.0)              |         | 1/3 (33.3)    | 1/3 (33.3)  |
| Unknown                               | 1/18 (5.6)             |         | 4/44 (9.1)    | 3/7 (42.9)  |
| **Condom Use α                       |                        |         |               |         |                       |         |
| Always                                | 2/112 (1.8)            | 0.165   | 7/35 (20.0)   | 0.062   | 9/18 (50.0)           | 0.938   |
| Sometimes                             | 0/29 (0.0)             |         | 3/22 (13.6)   | 8/19 (41.2)  |
| Never                                 | 0/8 (0.0)              |         | 7/81 (8.6)    | 5/9 (55.5)  |
| Unknown                               | 0/5 (0.0)              |         | 1/3 (20.0)    | 2/3 (40.0)  |
| **Sexually Transmitted Infection     |                        |         |               |         |                       |         |
| Yes                                   | 2/69 (2.9)             | 0.201   | 4/39 (10.2)   | 0.779   | 8/10 (80.0)           | 0.031   |
| No                                    | 0/94 (0.0)             |         | 14/102 (13.7)| 15/40 (37.5)|                       |
| Unknown                               | 1/2                    |         |               |         |                       |         |
| **Oral Intercourse                   |                        |         |               |         |                       |         |
| Yes                                   | 2/115 (1.7)            | 1       | 5/54 (9.2)    | 0.275   | 9/25 (36.0)           | 0.138   |
| No                                    | 0/37 (0.0)             |         | 10/60 (16.6)  | 13/21 (61.9)|                       |
| Unknown                               | 0/2 (0.0)              |         | 3/27 (11.1)   | 2/3 (40.0)  |
| **Anal Intercourse                   |                        |         |               |         |                       |         |
| Yes                                   | 1/114 (0.8)            | 0.438   | 7/50 (14.0)   | 0.780   | 8/19 (42.1)           | 0.561   |
| No                                    | 1/38 (2.6)             |         | 8/72 (11.1)   | 14/27 (51.8)|                       |
| Unknown                               | 0/2 (0.0)              |         | 1/21 (4.8)    | 2/3 (40.0)  |
| **Tattoo                              |                        |         |               |         |                       |         |
| Yes                                   | 1/42 (2.4)             | 0.472   | 0/13 (0)      | 0.372   | 3/6 (50.0)            | 1       |
| No                                    | 1/112 (0.9)            |         | 18/130        | 13/21 (61.9)|                       |
| Unknown                               | 0                      |         |               | 1/1 (100.0)|                       |
| **Piercing                            |                        |         |               |         |                       |         |
| Yes                                   | 1/15 (6.6)             | 0.186   | 0/2 (0.0)     | 1       | 2/2 (100.00)          | 0.215   |
| No                                    | 1/139 (0.7)            |         | 18/141 (12.7)| 21/47 (44.7)|                       |
| Unknown                               | 0                      |         |               | 1/2 (50.0)  |
| **Transfusion of Blood/Plasma        |                        |         |               |         |                       |         |
| Yes                                   | 0/16 (0.0)             | 1       | 14/90 (15.5)  | 0.110   | 21/35 (60)            | 0.004   |
| No                                    | 2/136 (1.5)            |         | 5/51 (5.9)    | 2/15 (13.3)|                       |
| Unknown                               | 0/2 (0.0)              |         | 1/2 (50.0)    | 1/1 (100.0)|                       |
| **Transfusion before 1994            |                        |         |               |         |                       |         |
| Yes                                   | 0/8 (0.0)              | 1       | 7/73 (9.6)    | 0.004   | 16/25 (64.0)          | 0.464   |
| No                                    | 0/8 (0.0)              |         | 7/73 (9.6)    | 5/11 (45.4)|                       |
| Unknown                               | 2/138 (1.4)            |         | 4/53 (7.5)    | 3/15 (20.0)|                       |
| **Attend Manicure                     |                        |         |               |         |                       |         |
| Yes                                   | 2/94 (2.1)             | 0.523   | 7/80 (8.7)    | 0.201   | 9/20 (45.0)           | 1       |
| No                                    | 0/59 (0.0)             |         | 10/62 (16.1)  | 14/30 (46.6)|                       |
| Unknown                               |                        |         |               |         |                       |         |
| **Injecting/Inhaled Drug Use          |                        |         |               |         |                       |         |
| Yes                                   | 1/34 (2.9)             | 0.393   | 3/8 (37.5)    | 0.064   | 3/6 (50.0)            | 1       |
| No                                    | 1/120 (0.8)            |         | 15/134 (11.2) | 20/43 (46.5)|                       |
| Unknown                               | 0/3 (0.0)              |         | 0/1 (0.0)     | 1/2 (50.0)  |

CRF = chronic renal failure; α Chi-Squared for trend; * Fisher’s exact test.
4. Discussion

In the present study, high HBV and HCV prevalence was found in HIV-positive (GI), haemodialysis CRF (GII), and coagulopathies (GIII) populations compared to the general population. We found HBsAg prevalence of 3.9%, 7% and 3.9%, anti-HBc prevalence of 28.6%, 55.9% and 31.4%, and anti-HCV prevalence of 1.3%, 12.6% and 47% in GI, GII and GIII, respectively. Pereira et al. [4,5] showed that the HBsAg prevalence ranged from 0.19% to 0.60%, total anti-HBc prevalence ranged from 8.1% to 10.3%, and anti-HCV prevalence was 1.38% (ranging from 0.68% to 2.60%) in the general population. In Brazil, the prevalence of hepatitis B and C varies according to the geographical region, risk factors, sociodemographic- and population-based characteristics [4,5].

HBV prevalence in HIV-infected individuals was similar to previous studies [14,16–18]. In the Northeast region of Brazil, Távora et al. [17] found a prevalence of HBV/HIV (3.7%) similar to the present study, despite the different profiles of the health services; we recruited individuals from outpatient HIV/AIDS clinics, while subjects in the previous study were recruited from the infectious disease hospital. Having more than five sexual partners per year and previous sexually transmitted infections correlated with HBV exposure probably due to the shared common transmission routes of both HIV and HBV, particularly through the sexual route [17,24]. As such, this highlights the importance of health education and vaccination programmes for this group to prevent the transmission of HBV.

In patients with CRF on haemodialysis, the prevalence of HBsAg (7%) and anti-HBc (55.9%) were higher compared to HIV-infected individuals, which could be due to repeated blood exposure during CRF maintenance therapy [25]. The prevalence of both were higher than the prevalence found in the Southeast region (5.5% of HBsAg and 4% of anti-HBc) [19] and in a multicentre Brazilian study (1.4% of HBV prevalence) [26], but lower than the HBsAg prevalence in the South (10%) [27] and Central-West region (46.7%) [28]. These studies showed variable HBV prevalence rates in CRF population that may have been influenced by differences in organizational structure or the work process at haemodialysis centres, which includes the frequency of hygiene and sterilization of equipment in the dialysis room, reuse of capillaries and distribution of patients according to the number of health professionals [8,27,29,30].

Patients with CRF on haemodialysis who were older and received 100 to 400 dollars in monthly family income had high anti-HBc prevalence. Older individuals could undergo longer haemodialysis periods, which increases the risk of HBV exposure [31]. In addition, these individuals had difficulty to maintain employment due to the length of time spent on haemodialysis and their clinical condition; these subjects typically received social security benefits (sickness benefit) as a source of income [31,32].

Among the coagulopathy group, the prevalence of HBsAg and total anti-HBc was 3.9% and 31.4%, respectively. These results were higher than those found in the South region of Brazil (HBsAg prevalence of 2.9% and prevalence of total anti-HBc of 28.5%) [33,34]. These differences may have been due to the classification of haemophilia and VWD that lead to frequent blood transfusion and a higher risk of exposure to HBV [12,22,23]. In this group, age, history of sexually transmitted disease and blood or plasma transfusion, were associated with a high risk of HBV infection (\(p < 0.05\)), which was similar to previous observations [35–37].

Regarding HCV infection, low anti-HCV prevalence (1.3%) was found in HIV-infected individuals compared to studies conducted in the Northeast region (5.4%) [17] and Southeast region of Brazil (4.6% and 6.4%) [14,16]; this was probably due to the small number of intravenous drug users enrolled in the present study. In CRF patients, the prevalence of anti-HCV was 12.6% which is lower than that found in studies conducted in the Southeast region (14.8%) [9], Northeast region (52%) [38] and South region of Brazil (13.57%) [39], which could have been the result of different standards of good practice for dialysis services [25,29,39]. In this group, receiving a blood transfusion before 1994 was associated with HCV infection (\(p = 0.004\)), as anti-HCV screening in Brazil was initiated in blood banks in 1993 [40].
In coagulopathy patients, anti-HCV prevalence was 47% which is higher than that found in the Southeast region (39.4%) [34], Northeast region (42.2%) [41] and South region of the country (34.16%) [34] and could have been the result of different types of coagulopathy included in each study. The anti-HCV prevalence was 34.9%, 29.7% and 12% in individuals affected by haemophilia A, haemophilia B and VWD, respectively [23]. In this group, a history of sexually transmitted disease and transfusion of blood and/or plasma were associated with high risk of HCV transmission \( (p < 0.05) \), which reinforced the view that coagulopathy patients who received multiple blood transfusions or blood products [39] prior to 1994 were most affected by HCV due to the lack of anti-HCV screening in blood banks before that date [35,36].

5. Conclusions

This study showed a high prevalence of HBV and HCV among the specific groups evaluated compared to the general population. Factors such as age, income, number of sexual partners, history of sexually transmitted disease, blood or plasma transfusion and transfusion before 1994 were associated with the higher prevalence of these infections. These data indicated the necessity of continuous diagnosis, follow-up and prevention of HBV and HCV infections in these groups to prevent clinical complications and the spread of these infections.

Acknowledgments: The authors would like to thank the health authorities from the recruitment centres health authorities from the recruitment centers for technical support, the Center for Integrated Medical Care of the University of Fortaleza, the PRONEFRON Group, the Outpatient clinic of Hereditary Coagulopathies of the Hematology and Hemotherapy Center of Ceará–Hemoce and, Juliana Custódio Miguel and Elisangela Ferreira da Silva from the Laboratory of Viral Hepatitis (LAHEP/FIOCRUZ) for technical assistance in laboratory testing. This research was supported by the Brazilian Ministry of Health, the Coordination of Improvement of Higher Education Personnel (CAPES), Brazilian National Council of Technological and Scientific Development (CNPq), and Oswaldo Cruz Foundation (FIOCRUZ).

Author Contributions: Jakeline R. Barbosa contributed to the study design, administered participant surveys, analysed and interpreted data, and drafted and revised the manuscript. Cristianne S. Bezerra and Filipe A. Carvalho-Costa assisted with the design of the study survey, data collection, data interpretation and manuscript revisions. Carolina Pimentel de Azevedo administered participant surveys, assisted with data collection and reviewed the manuscript. Geane L. Flores assisted with data interpretation and with writing and revising the manuscript. Jeová Keny Baima Colares, Danielle Malta Lima and Elisabeth Lampe participated conceptualization of the study, laboratory tests and manuscript reviews. Lívia Melo Villar conceived the study, managed data acquisition, participated in study design and coordination and reviewed and revised the manuscript. All authors read and approved the final manuscript.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. McMahon, B.J. The natural history of chronic hepatitis B virus infection. Semin. Liver Dis. 2004, 24, 17–21. [CrossRef] [PubMed]
2. Seeff, L.B. The history of the “natural history” of hepatitis C (1968–2009). Liver Int. 2009, 29, 89–99. [CrossRef] [PubMed]
3. World Health Organization—WHO. Hepatitis B and Hepatitis C. Updated April 2017. Available online: http://www.who.int/mediacentre/factsheets/en/ (accessed on 5 May 2017).
4. Pereira, L.M.M.B.; Martelli, C.M.T.; Merchán-Hamann, E.; Montarroyos, U.R.; Braga, M.C.; Lima, M.L.C.; Cardoso, M.R.; Turchi, M.D.; Costa, M.A.; de Alencar, L.C.; et al. Population-based multicentric survey of hepatitis B infection and risk factor differences among three regions in Brazil. Am. J. Trop. Med. Hyg. 2009, 81, 240–247. [PubMed]
5. Pereira, L.M.M.B.; Martelli, C.M.T.; Moreira, R.C.; Merchant-Hamman, E.; Stein, A.T.; Cardoso, M.R.A.; Figueiredo, G.M.; Montarroyos, U.R.; Braga, C.; Turchi, M.D.; et al. Prevalence and risk factors of hepatitis C virus infection in Brazil, 2005 through 2009: A cross-sectional study. BMC Infect. Dis. 2013, 13, 60. [CrossRef] [PubMed]
6. Franchini, M.; Mannucci, P.M. Co-morbidities and quality of life in elderly persons with haemophilia. Br. J. Haematol. 2009, 148, 522–533. [CrossRef] [PubMed]
1. Edey, M.; Barraclough, K.; Johnson, D.W. Review article: Hepatitis B and dialysis. Nephrology 2010, 15, 137–145. [CrossRef] [PubMed]
2. Moreira, R.C.; Deguti, M.M.; Lemos, M.F.; Saraceni, C.P.; Obá, I.T.; Spina, A.M.M.; Nascimento-Lima, A.S.; Fares, J.; Azevedo, R.S.; Gomes-Gouvêa, M.S.; et al. HBV markers in haemodialysis Brazilian patients: A prospective 12-month follow-up. Mem. Inst. Oswaldo Cruz 2010, 105, 107–108. [CrossRef] [PubMed]
3. Leão, J.R.; Pace, F.H.L.; Chebli, J.M.F. Infecção pelo virus da hepatite C em pacientes em hemodiálise: Prevalência e fatores de risco. Arq. Gastroenterol. 2010, 47, 28–34. [CrossRef] [PubMed]
4. Joukar, F.; Besharati, S.; Mirpour, H.; Mansour-Ghanaei, F. Hepatitis C and hepatitis B seroprevalence and associated risk factors in hemodialysis patients in Guilan province, north of Iran. Hepat. Mon. 2011, 11, 178–181. [PubMed]
5. Kretzer, I.F.; Livramento, A.; Cunha, J.; Gonçalves, S.; Tosin, I.; Spada, C.; Treitinger, A. Hepatitis C worldwide and in Brazil: Silent epidemic—Data on disease including incidence, transmission, prevention, and treatment. Sci. World J. 2014, 2014. [CrossRef] [PubMed]
6. Ferreira, A.A.; Leite, I.C.G.; Bustamante-Teixeira, M.T.; Guerra, M.R. Hemophilia A in Brazil—Epidemiology and treatment developments. J. Blood Med. 2014, 5, 175–184. [CrossRef] [PubMed]
7. Brandão, N.A.; Pirheimer, L.A.; Martelli, C.M.; Turchi, M.D. Prevalence of hepatitis B and C infection and associated factors in people living with HIV in midwestern Brazil. Braz. J. Infect. Dis. 2015, 19, 426–430. [CrossRef] [PubMed]
8. Flores, G.L.; Almeida, A.J.; Miguel, J.C.; Cruz, H.M.; Portilho, M.M.; Scaliion, L.P.; Marques, V.A.; Lewis-Ximenez, L.L.; Lampe, E.; Villar, L.M. A cross section study to determine the prevalence of antibodies against HIV infection among hepatitis B and C infected individuals. Int. J. Environ. Res. Public Health 2016, 13, 314. [CrossRef] [PubMed]
9. Lacombe, K.; Rockstroh, J. HIV and viral hepatitis coinfections: Advances and challenges. Gut 2012, 61 (Suppl. 1), i47–i58. [CrossRef] [PubMed]
10. Farias, N.S.I.; Coelho, D.M.; Oliveira, U.B.; Binelli, C.A. Cointeção pellos virus das hepatites B ou C e da imunodeficiência adquirida: Estudo exploratório no Estado de São Paulo, Brasil, 2007 a 2010. Epidemiol. Serv. Saúde 2012, 21, 475–486. [CrossRef]
11. Távora, L.G.F.; Hyppolito, E.B.; Cruz, J.N.M.; Portela, N.M.B.; Pereira, S.M.; Veras, C.M. Hepatitis B, C and HIV co-infections seroprevalence in a northeast Brazilian center. Arq. Gastroenterol. 2013, 50, 277–280. [CrossRef] [PubMed]
12. Oliveira, S.B.; Merchán-Hamann, E.; Amorim, L.D.A.F. HIV/AIDS coinfection with the hepatitis B and C viruses in Brazil. Cad. Saúde Pública 2014, 30, 433–438. [CrossRef] [PubMed]
13. Marquesini, G.; Gonçalves, N.S.L.; Gonçalves Júnior, F.L. Prevalência dos marcadores sorológicos dos virus da hepatite B (VHB) e da hepatite C (VHC) em hemodialisados. Rev. Panam. Infectol. 2008, 10, 23–27.
14. Mannucci, P.M.; Tuddenham, E.G.D. The haemophiliac—from royal genes to gene therapy. N. Engl. J. Med. 2001, 344, 1773–1779. [CrossRef] [PubMed]
15. Federici, A.B.; Santagostino, E.; Rumi, M.G.; Russo, A.; Mancuso, M.E.; Soffredini, R.; Mannucci, P.M.; Colombo, M. The natural history of hepatitis C virus infection in Italian patients with von Willebrand’s disease: A cohort study. Haematologica 2006, 91, 503–508. [PubMed]
16. Brazilian Health Ministry. Secretary of Health Care. General Coordination of Blood and Hemoderivatives. In Profile of Hereditary Coagulopathies in Brazil; Brazilian Health Ministry: Brasília, Brazil, 2015; p. 62.
17. Rezende, S.M.; Pinheiro, K.; Caram, C.; Genovez, G.; Barca, D. Registry of inherited coagulopathies in Brazil: First report. Haemostasia 2009, 15, 142–149. [CrossRef] [PubMed]
18. Kapembwa, K.C.; Goldman, J.D.; Lakhí, S.Y.; Bowa, K.; Vermund, S.H.; Mulenga, J.; Chama, D.; Chi, B.H. HIV, hepatitis B, and hepatitis C in Zambia. J. Glob. Infect. Dis. 2011, 3, 269–274. [CrossRef] [PubMed]
19. Halle, M.P.; Choukem, S.P.; Kaze, F.F.; Ashuntantang, G.; Tchamago, V.; Mboue-Djiekia, Y.; Temfack, E.; Luma, H.N. Hepatitis B, hepatitis C, and human immune deficiency virus seroconversion positivity rates and their potential risk factors among patients on maintenance hemodialysis in Cameroon. Iran. J. Kidney Dis. 2016, 10, 304–309. [PubMed]
20. Sesso, R.C.; Lopes, A.A.; Thomé, F.S.; Lugon, J.R.; Santos, D.R. Brazilian Chronic Dialysis Survey 2013—Trend analysis between 2011 and 2013. J. Bras. Nefrol. 2014, 36, 476–481. [CrossRef] [PubMed]
27. Carrilho, F.J.; Moraes, C.R.; Pinho, J.R.R.; Mello, I.M.V.G.C.; Bertolini, D.A.; Lemos, M.F.; Moreira, R.C.; Bassit, L.C.; Cardoso, R.A.; Ribeiro-dos-Santos, G.; et al. Hepatitis B virus infection in Haemodialysis Centres from Santa Catarina State, southern Brazil: Predictive risk factors for infection and molecular epidemiology. *BMC Public Health* 2004, 4, 13. [CrossRef] [PubMed]

28. Carneiro, M.A.S.; Martins, R.M.B.; Teles, A.S.; Silva, A.S.; Lopes, C.L.; Cardoso, D.D.P.; Vanderborght, B.O.; Yoshida, C.F. Hepatitis C prevalence and risk factors in hemodialysis patients in central Brazil: A survey by polymerase chain reaction and serological methods. *Men. Inst. Oswaldo Cruz* 2001, 96, 765–769. [CrossRef]

29. Santos, M.A.M.; Souto, F.J.D. Infection by the hepatitis C virus in chronic renal failure patients undergoing hemodialysis in Mato Grosso State, central Brazil: A cohort study. *BMC Public Health* 2007, 7, 32. [CrossRef] [PubMed]

30. Chang, J.M.; Huang, C.F.; Chen, S.C.; Daí, C.Y.; Yeh, M.L.; Huang, J.F.; Kuo, H.T.; Chuang, W.L.; Yu, M.L.; Hwang, S.J.; et al. Discrepancy between serological and virological analysis of viral hepatitis in hemodialysis patients. *Int. J. Med. Sci.* 2014, 11, 436–441. [CrossRef] [PubMed]

31. Zambonato, T.K.; Thomé, F.S.; Gonçalves, L.F.S. Socioeconomic status of patients with end-stage renal disease on dialysis in northwestern Rio Grande do Sul—Brazil. *J. Bras. Nefrol.* 2008, 30, 192–199.

32. Carmo, R.A.; Oliveira, G.C.; Guimarães, M.D.C.; Oliveira, M.S.; Lima, A.A.; Buzek, S.C.; Corrêa-Oliveira, R.; Rocha, M.O.C. Hepatitis C virus infection among Brazilian hemophiliacs: A virological, clinical and epidemiological study. *Braz. J. Med. Biol. Res.* 2002, 35, 589–598. [CrossRef] [PubMed]

33. Fontes, E.M.; Amorim, L.; Carvalho, S.M.; Farah, M.B. Hemophilia care in the state of Rio de Janeiro, Brazil. *Rev. Panam. Salud Publica/Pan Am. J. Public Health* 2003, 13, 124–128. [CrossRef]

34. Hoepers, A.T.C. Hemofilia no estado de Santa Catarina: Estudo clínico. *Rev. Bras. Hematol. Hemoter.* 2008, 30, 172. [CrossRef]

35. Ziaee, M.; Namaei, M.H.; Azarkar, G. The prevalence of HTLV-1 and its co-infection with HCV, HBV and HIV in hemophilic patients. *Pak. J. Med. Sci.* 2015, 31, 1246–1249. [CrossRef] [PubMed]

36. Medeiros, M.T.G.; Lima, J.M.C.; Lima, J.W.O.; Medeiros, M.M.C.; Coelho-Filho, J.M.C. Prevalence and associated factors to hepatitis C in hemodialysis patients in Brazil. *Rev. Saúde Pública* 2004, 38, 187–193. [CrossRef] [PubMed]

37. Sassaki, L.; Bertolini, D.A.; Arraes, S.M.A.A. Soroprevalência da Hepatite C em pacientes sob tratamento de diálise da região de Toledo, Paraná. *Arq. Mudi* 2006, 10, 5–9.

38. Brasil. Ministério da Saúde. Portaria n 1.376 de 19 de Novembro de 1993. Available online: http://portal.anvisa.gov.br/legislacao# (accessed on 17 March 2017).

39. Silva, L.K.; Silva, M.B.S.; Lopes, G.B.; Rodart, I.F.; Costa, F.Q.; Santana, N.P.; Paraná, R.; Santana, A.; Reis, M.G. Prevalence of hepatitis C virus infection and HCV genotypes among hemophiliacs in the State of Bahia, northeastern Brazil: Analysis of serological and virological parameters. *Rev. Soc. Bras. Med. Trop.* 2005, 38, 496–502. [CrossRef] [PubMed]